Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 14/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493431 | 0.83 | KCNN4 (0.30) | KCNN4 | |
| SCHEMBL14112954 | 0.79 | KCNN4 (0.54) | KCNN4 | |
| SCHEMBL1493508 | 0.78 | KCNN4 (0.44) | KCNN4ALDH1A1TSHR | |
| SCHEMBL1493409 | 0.77 | ALDH1A1 (0.56) | KCNN4ALDH1A1MAPTTSHRNPSR1 | |
| SCHEMBL1493541 | 0.77 | ALDH1A1 (0.37) | KCNN4P2RX7ALDH1A1TSHR | |
| SCHEMBL1610810 | 0.73 | KCNN4 (0.40) | KCNN4ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL1493427 | 0.73 | POLB (0.47) | ALDH1A1SMN1; SMN2POLBMAPTNPSR1 | |
| SCHEMBL1493415 | 0.73 | TSHR (0.52) | ALDH1A1SMN1; SMN2TSHRNPSR1 | |
| SCHEMBL1612399 | 0.71 | P2RX7 (0.44) | KCNN4P2RX7ALDH1A1 | |
| SCHEMBL8048128 | 0.71 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2POLBMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KCNN4 869/4885P2RX7 150/4885ALDH1A1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.